Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

Breast Cancer Research and Treatment
Erik J BlokPeter J K Kuppen

Abstract

Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy. The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane. The numbers of CD8-positive TILs were analysed for correlations with disease-free survival (DFS) and overall survival (OS). A similar analysis was performed on 2596 patients in the TEAM trial who were randomized between the sequential scheme and the exemestane monotherapy. In the first cohort, patients with low (below median) numbers of CD8-positive TILs had a univariate hazard ratio (HR) for DFS of 0.27 (95% CI 0.13-0.55) in favour of treatment with exemestane, whereas this benefit was not observed in patients with high numbers of CD8-positive TILs (HR 1.34, 95% CI 0.71-2.50, HR for interaction 5.02, p = 0.001). In the second cohort, patients with low numbers of CD8-positive TILs showed a benefit of exemestane treatment on recurrence...Continue Reading

References

Jan 5, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·R L CampD L Rimm
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniele GeneraliStephen B Fox
Jan 21, 2011·Lancet·Cornelis J H van de VeldeStephen E Jones
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sahar M A MahmoudAndrew R Green
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Judith M BlissR Charles Coombes
Jan 5, 2013·The Open AIDS Journal·Valéria FerreiraLuiz Cláudio Arraes
Mar 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anita K DunbierMitch Dowsett
Aug 21, 2013·Joint, Bone, Spine : Revue Du Rhumatisme·Daniel WendlingXavier Pivot
Nov 8, 2013·Breast Cancer Research and Treatment·Esther M de KruijfPeter J K Kuppen
Mar 19, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qiong GaoMitch Dowsett
Jun 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H R AliC Caldas
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvia AdamsSunil S Badve
Aug 9, 2016·The Journal of Pathology. Clinical Research·Jan BudcziesAlbrecht Stenzinger
May 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James P MordenR Charles Coombes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
V SpeirsPathIES Sub-Committee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gunter von MinckwitzSibylle Loibl
© 2022 Meta ULC. All rights reserved